# Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation

> **NCT01116232** · PHASE2 · TERMINATED · sponsor: **Barbara Ann Karmanos Cancer Institute** · enrollment: 4 (actual)

## Conditions studied

- Chronic Myeloproliferative Disorders
- Graft Versus Host Disease
- Leukemia
- Lymphoma
- Lymphoproliferative Disorder
- Multiple Myeloma and Plasma Cell Neoplasm
- Myelodysplastic Syndromes
- Myelodysplastic/Myeloproliferative Neoplasms

## Interventions

- **BIOLOGICAL:** anti-thymocyte globulin
- **BIOLOGICAL:** rituximab
- **DRUG:** sirolimus
- **DRUG:** tacrolimus
- **OTHER:** laboratory biomarker analysis
- **PROCEDURE:** allogeneic hematopoietic stem cell transplantation
- **PROCEDURE:** management of therapy complications
- **PROCEDURE:** peripheral blood stem cell transplantation

## Key facts

- **NCT ID:** NCT01116232
- **Lead sponsor:** Barbara Ann Karmanos Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-08
- **Primary completion:** 2013-05
- **Final completion:** 2013-06
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Lack of funding.
- **Last updated:** 2019-03-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01116232

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01116232, "Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01116232. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*